title: Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.
abstract: BACKGROUND
  Patients with chronic kidney disease (CKD) have an increased risk for cardiovascular events (CVE). Uraemic dyslipidaemia, which is characterized by low HDL-cholesterol (HDL-C) and elevated triglycerides' levels, may contribute to this elevated cardiovascular risk. Cholesteryl ester transfer protein (CETP) lowers HDL-C by transferring cholesterol esters to LDL and VLDL particles. We tested the hypothesis that CETP activity is associated with CVE in patients with CKD stage V.
  
  
  METHODS
  We measured CETP activity and cholesterol levels in 69 haemodialysis patients. CVE and death were prospectively assessed over a follow-up period of 48 months.
  
  
  RESULTS
  CETP activity was negatively correlated with HDL-C levels in patients without lipid-lowering medication (r = -0.379, P = 0.005). We found no difference in CETP activity in patients with cardiovascular disease at baseline compared to patients without cardiovascular disease. The same was true for incident CVE during the follow-up. When stratifying patients by median CETP activity, patients with high CETP activity did not have an increased risk for CVE (P = 0.901 by the log-rank test) or death (P = 0.615). Similarly, after stratifying patients by median HDL-C no increased risk for CVE (P = 0.780) or death (P = 0.838) was found in patients with low HDL-C.
  
  
  CONCLUSIONS
  In summary, although CETP activity correlated with HDL-C levels, neither high CETP activity nor low HDL-C was associated with CVE in CKD stage V patients. Thus, pharmacological modification of HDL-C by CETP inhibitors seems to be of questionable value in these patients.
authors.affiliation: Department of Medicine IV, Saarland University, Homburg/Saar, Germany. Sarahseiler@gmx.de
authors.forename: Sarah
authors.initials: S
authors.lastname: Seiler
authors.forename: Axel
authors.initials: A
authors.lastname: Schlitt
authors.forename: Xian-Cheng
authors.initials: XC
authors.lastname: Jiang
authors.forename: Christof
authors.initials: C
authors.lastname: Ulrich
authors.forename: Stefan
authors.initials: S
authors.lastname: Blankenberg
authors.forename: Karl J
authors.initials: KJ
authors.lastname: Lackner
authors.forename: Matthias
authors.initials: M
authors.lastname: Girndt
authors.forename: Karl
authors.initials: K
authors.lastname: Werdan
authors.forename: Michael
authors.initials: M
authors.lastname: Buerke
authors.forename: Danilo
authors.initials: D
authors.lastname: Fliser
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Heine
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D002908:Chronic Disease; D015331:Cohort Studies; D001026:Coronary Artery Bypass; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D007674:Kidney Diseases / Q000097:blood* / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D015607:Stents; D020521:Stroke / Q000453:epidemiology*
chemical_list: D015415:Biomarkers; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL